The treatment of herpes simplex infections: An evidence-based review

Archives of Internal Medicine

Volumn 168, Issue 11, 2008, Pages 1137-1144

  Cernik, Christina ^a   Gallina, Kelly ^b   Brodell, Robert T ^a,c,d,e  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Adena Health System   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e Brodell Medical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PENCICLOVIR; PLACEBO; VALACICLOVIR;

CLINICAL COMPETENCE; CLINICAL TRIAL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EVIDENCE BASED MEDICINE; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RECURRENT INFECTION; REVIEW; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; SOCIAL STATUS; SYMPTOM; TOOTH EXTRACTION; TREATMENT DURATION; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS SHEDDING; VIRUS TRANSMISSION;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVIDENCE-BASED MEDICINE; HERPES GENITALIS; HERPES LABIALIS; HUMANS; RECURRENCE; RISK FACTORS; VALINE;

EID: 45149131920     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.11.1137     Document Type: Review

References (106)

1. Klein RS. Epidemiology of herpes simplex virus type 1 infection. http://uptodate.com/. Accessed February 1, 2008.
2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973.
3. Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis. 2006;12(3):254-270.
4. Kolokotronis A, Doumas S. Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis. Clin Microbiol Infect. 2006;12(3):202-211.
5. 2 laser resurfacing. Cutis. 2003;72(4):327-328.
6. Nikkels AF, Pièrard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol. 2002;3(7):475-487.
7. Miller CS, Cunningham LL, Lindroth JE, Avdiushko SA. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures. J Am Dent Assoc. 2004;135(9):1311-1318.
8. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med. 1993;118(4):268-272.
9. Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis. 2003;71(3):239-242.
10. Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol. 2006;55(1):47-53.
11. Woo S, Challacombe SJ. Management of recurrent oral herpes simplex infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(suppl):S12.e1-S12.e18.
12. Felman YM, Nikitas JA. Genital herpesvirus infection. N Y State J Med. 1979;79(8):1216-1218.
13. Engel JP. Long-term suppression of genital herpes. JAMA. 1998;280(10):928-929.
14. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42(1):8-13.
15. Solomon L, Cannon MJ, Reyes M, Graber JM, Wetherall NT, Reeves WC; Task Force on Herpes Simplex Virus Resistance. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex Transm Infect. 2003;79(6):456-459.
16. Sauerbrei A, Wutzler P. Herpes simplex and varicella zoster virus infections during pregnancy: current concepts of prevention, diagnosis, and therapy, part 1: herpes simplex virus infections. Med Microbiol Immunol. 2007;196(2):89-94.
17. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med. 1999;131(1):14-20.
18. Rosen T. Sexually transmitted diseases 2006: a dermatologist's view. Cleve Clin J Med. 2006;73(6):537-538, 542, 544-545.
19. Mindel A. Genital herpes: the forgotten epidemic. J Herpes. 1994;1(2):39-48.
20. Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1527-1534.
21. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ. 1997;314(7097):1800-1803.
22. Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. J Can Dent Assoc. 2002;68(4):247-251.
23. Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis. 1990;161(2):185-190.
24. Spruance S, Jones T, Blatter M, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother. 2003;47(3):1072-1080.
25. Chacko M, Weinberg J. Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications. Cutis. 2007;80(1):77-81.
26. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T; Acyclovir Cream Study Group. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46(7):2238-2243.
27. Chon T, Nguyen L, Elliott TC. Clinical inquiries: what are the best treatments for herpes labialis? J Fam Pract. 2007;56(7):576-578.
28. Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL. Effective treatment of herpes simplex with penciclovir cream: combined results of two trials. J Am Dent Assoc. 2002;133(3):303-309.
29. Fiddian AP, Yeo JM, Stubbings R, Dean D. Successful treatment of herpes labialis with topical acyclovir. Br Med J (Clin Res Ed). 1983;286(6379):1699-1701.
30. Van Vloten WA, Swart RN, Pot F. Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections. J Antimicrob Chemother. 1983;12(suppl B):89-93.
31. Femiano F, Gombos F, Scully C. Recurrent herpes labialis: efficacy of topical therapy with penciclovir compared with acyclovir. Oral Dis. 2001;7(1):31-33.
32. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA. 1997;277(17):1374-1379.
33. Raborn GW, McGaw WT, Grace M, Houle L. Herpes labialis treatment with acyclovir 5 per cent ointment. J Can Dent Assoc. 1989;55(2):135-137.
34. Raborn GW, McGaw WT, Grace M, Percy J, Samuels S. Herpes labialis treatment with the acyclovir 5% modified aqueous cream: a double-blind randomized trial. Oral Surg Oral Med Oral Pathol. 1989;67(6):676-679.
35. Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis. 1999;179(2):303-310.
36. Boon R, Goodman JJ, Martinez J, Marks GL, Gamble M, Welch C. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Clin Ther. 2000;22(1):76-90.
37. Lin L, Chen XS, Cui PG, et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicenter, acyclovir-controlled trial. J Dermatolog Treat. 2002;13(2):67-72.
38. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA. 1984;252(9):1147-1151.
39. Wald A, Benedetti J, Davis G, Remington M, Winter C, Corey L. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections. Antimicrob Agents Chemother. 1994;38(2):174-176.
40. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R; Valaciclovir International Herpes Simplex Virus Study Group. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis. 1997;24(8):481-486.
41. Fiddian AP, Halsos AM, Kinge BR, Nilsen AE, Wikstrom K. Oral acyclovir in the treatment of genital herpes preliminary report of a multicenter trial. Am J Med. 1982;73(1A):335-337.
42. Loveless M, Sacks SL, Harris JR. Famciclovir in the managementof first-episode genital herpes. Infect Dis Clin Pract. 1997;6(1)(suppl): S12-S16.
43. Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs. 2006;66(18):2397-2416.
44. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA. 1984;251(16):2103-2107.
45. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valacyclovir versus acyclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med. 1997;73(2):110-116.
46. Goldberg LH, Kaufman R, Conant MA, et al. Oral acyclovir for episodic treatment of recurrent genital herpes. J Am Acad Dermatol. 1986;15(2, pt 1):256-264.
47. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis. 2002;34(7):944-948.
48. Saiag P, Praindhui D, Chastang C. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. J Antimicrob Chemother. 1999;44(4):525-531.
49. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis. 2002;34(7):958-962.
50. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K; Valaciclovir HSV Study Group. A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med. 1996;156(15):1729-1735.
51. Sacks SL, Aoki FY, Siaz-Mitoma F, Sellors J, Shafran SD; Canadian Famciclovir Study Group. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA. 1996;276(1):44-49.
52. Sacks SL, Aoki FY, Martel AY, Shafran SD, Lassonde M. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin Infect Dis. 2005;41(8):1097-1104.
53. Tyring SK, Douglas JM, Corey L, Spruance SL, Esmann J; Valaciclovir International Study Group. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol. 1998;134(2):185-191.
54. Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis. 2004;39(suppl 5):S258-S266.
55. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS. 2000;14(9):1211-1217.
56. Chen XS, Han GZ, Guo ZP, Lu NZ, Chen J, Wang JB. A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicenter trial. Int J STD AIDS. 2000;11(9):568-573.
57. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982;306(22):1313-1319.
58. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous, and oral therapy. J Antimicrob Chemother. 1983;12(suppl B):79-88.
59. Centers for Disease Control and Prevention, Division of STD Prevention. Sexually transmitted diseases: treatment guidelines 2006. http://www.cdc.gov/ std/treatment/2006/genital-ulcers.htm#genulc3. Accessed March 7, 2008.
60. Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA. 1998;280(10):887-892.
61. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238-246.
62. Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. JAMA. 1991;265(6):747-751.
63. Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Recurrent genital herpes treatments and their impact on quality of life. Pharmacoeconomics. 2003;21(12):853-863.
64. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11-20.
65. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med. 1997;157(3):343-349.
66. Gilbert SC. Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. J Drugs Dermatol. 2007;6(4):400-405.
67. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after skin resurfacing. Dermatol Surg. 1999;25(3):242-246.
68. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled, double-blind trial of oral acyclovir. N Engl J Med. 1984;310(24):1545-1550.
69. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex infection: a multicenter double-blind trial. JAMA. 1988;260(2):201-206.
70. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS; Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir. J Infect Dis. 1994;169(6):1338-1341.
71. Goldberg LH, Kaufman R, Kurtz TO, et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol. 1993;129(5):582-587.
72. Mostow SR, Mayfield JL, Marr JJ, Drucker JL. Suppression of recurrent genital herpes by single daily dosages of acyclovir. Am J Med. 1988;85(2A):30-33.
73. Mattison HR, Reichman RC, Benedetti J, et al. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. Am J Med. 1988;85(2A):20-25.
74. Baker DA, Blythe JG, Kaufman R, Hale R, Portnoy J. One-year suppression of frequent recurrences of genital herpes with oral acyclovir. Obstet Gynecol. 1989;73(1):84-87.
75. Straus SE, Croen KD, Sawyer MH, et al. Acyclovir suppression of frequently recurring genital herpes: efficacy and diminishing need during successive years of treatment. JAMA. 1988;260(15):2227-2230.
76. Sacks SL, Fox R, Levendusky P, et al. Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. Sex Transm Dis. 1988;15(1):58-62.
77. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984;310(24):1551-1556.
78. Mindel A, Weller IV, Faherty A, et al. Prophylactic oral acyclovir in recurrent genital herpes. Lancet. 1984;2(8394):57-59.
79. Patel R, Bodsworth NJ, Woolley P, et al; International Valacyclovir HSV Study Group. Valacyclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin Med. 1997;73(2):105-109.
80. Ormrod D, Scott LJ, Perry CM. Valacyclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Drugs. 2000;59(4):839-863.
81. Reitano M, Tyring S, Lang W, et al. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis. 1998;178(3):603-610.
82. Tyring SK, Diaz-Mitoma F, Shafran SD, Locke LA, Sacks SL, Young CL. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J Cutan Med Surg. 2003;7(6):449-454.
83. Kerob D, Assier-Bonnet H, Esnault-Gelly P, Blanc F, Saiag P. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol. 1998;134(7):876-877.
84. Olson J, Robles DT, Kirby P, Colven R. Kaposi varicelliform eruption (eczema herpeticum). Dermatol Online J. 2008;14(2):18. http://dermatology.cdlib.org/142/case_presentations/eczemaherp/olson.html/. Accessed April 7, 2008.
85. Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol. 2000;118(8):1030-1036.
86. McNeeley DF, Polsky B. Prophylaxis of viral infections in patients with cancer. Infect Med. 1995;12(5):203-204, 207-210.
87. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(1):21-28.
88. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21(2):311-320.
89. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ. Valacyclovir versus acyclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS. 2002;13(1):12-21.
90. Fife KH, Warren TJ, Ferrera RD, et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(10):1321-1327.
91. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(7):1009-1016.
92. Spruance SL, Hamill ML, Hoge WS, Davis LG, Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA. 1988;260(11):1597-1599.
93. Rooney JF, Straus SE, Mannix ML, et al. UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir. J Infect Dis. 1992;166(3):500-506.
94. Nelson MA. Stopping the spread of herpes simplex: a focus on wrestlers. Phys Sportsmed. 1992;20(10):117-127.
95. Raborn GW, Martel AY, Grace MGA, McGaw WT. Herpes labialis in skiers: randomized clinical trial of acyclovir cream versus placebo. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84:641-645.
96. Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg. 2002;28(4):331-336.
97. Guinan ME, MacCalman J, Kern ER, Overall JC, Spruance SL. The course of untreated recurrent genital herpes simplex infection in 27 women. N Engl J Med. 1981;304(13):759-763.
98. Segal AL, Katcher AH, Brightman VJ, Miller MF. Recurrent herpes labialis, recurrent aphthous ulcers, and the menstrual cycle. J Dent Res. 1974;53(4):797-803.
99. Myśliwska J, Trzonkowski P, Bryl E, Lukaszuk K, Myesliwski A. Lower interleukin-2 and higher serum tumor necrosis factor-a levels are associated with perimenstrual, recurrent, facial herpes simplex infection in young women. Eur Cytokine Netw. 2000;11(3):397-406.
100. Prober CG. Reducing the risk of perinatal transmission of herpes simplex virus type 2. Infect Med. 1993;10(3):21-24, 27-28, 44.
101. Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD Jr. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol. 2003;102(6):1396-1403.
102. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol. 2001;9(2):75-80.
103. Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol. 2006;108(1):141-147.
104. Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol. 2006;194(3):774-781.
105. Rosenbaum GS, Strampfer MJ, Cunha BA. Herpes gladiatorum in a male wrestler. Int J Dermatol. 1990;29(2):141-142.
106. Anderson BJ. Prophylactic valacyclovir to prevent outbreaks of primary herpes gladiatorum at a 28-day wrestling camp. Jpn J Infect Dis. 2006;59(1):6-9.